Guangzhou Yuansheng Pharmaceutical Technology

Guangzhou Yuansheng Pharmaceutical Technology is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative small molecule therapeutics. The company's research and development efforts are primarily focused on oncology and autoimmune diseases, aiming to provide effective treatments for advanced cancers. Its lead clinical candidate, YS-101, is a multi-target kinase inhibitor currently being evaluated in Phase 1/2 clinical trials for various solid tumors. Yuansheng Pharmaceutical leverages its internal R&D capabilities to advance a pipeline of novel drug candidates designed to address significant unmet medical needs in the global market. The company is headquartered in the Guangzhou Science City and benefits from a strong regional network of investors and academic collaborators.